Literature DB >> 2932037

Inactivation of atracurium in human and rat plasma.

V Nigrovic, J B Pandya, M Auen, A Wajskol.   

Abstract

The contribution of enzyme-catalyzed hydrolysis to inactivation of atracurium in human and rat plasma was determined in vitro by inhibiting the enzyme carboxylesterase with triorthotolyl phosphate. The inhibitor was removed by centrifugation and aspiration. Atracurium was then added to both the control and the inhibited plasma samples, and all samples were incubated at 37 degrees C for 45 min. The amount of atracurium present in aliquots of plasma was determined using a bioassay technique in anesthetized rats. Inactivation of atracurium proceeded rapidly in control rat plasma but was markedly slowed in samples treated with the inhibitor of carboxylesterase. In contrast, the inactivation was slow in control human plasma, and inhibition of carboxylesterase produced only marginal, if any, effects. We conclude that the inactivation of atracurium proceeds, in part, by enzyme-catalyzed ester hydrolysis. In species with high enzyme activity in plasma, e.g., the rat, enzyme-catalyzed hydrolysis is clearly evident. In humans, the level of enzyme activity is low and the contribution of enzyme-catalyzed inactivation is less manifest. By exclusion, Hofmann elimination or other reactions probably represent the major inactivation pathway in humans.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932037

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

2.  Reactivity and toxicity of atracurium and its metabolites in vitro.

Authors:  V Nigrovic; J B Pandya; J E Klaunig; K Fry
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

Review 3.  New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.

Authors:  C S Reilly; W S Nimmo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

4.  Use of atracurium in a patient with plasma cholinesterase deficiency.

Authors:  N Donen
Journal:  Can J Anaesth       Date:  1987-01       Impact factor: 5.063

5.  Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.

Authors:  V Nigrovic; M Banoub
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.